People
The U.S. Food and Drug Administration is set to rule on Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase (SYK) inhibitor, for adult patients with chronic or persistent immune thrombocytopenia (ITP) on April 17.
The move is part of the company’s strategy as it shifts from a consumer products company into a health tech company.
The news was disclosed by Ruyi He, MD, Chief Scientist of the CFDA and the Center for Drug Evaluation.
In the world of Alzheimer’s disease research, the names of some companies attempting to find an efficacious therapy stand out.
A federal judge has temporarily blocked the Trump administration’s efforts to wind down DACA.
MiMedx’s problems with short sellers continues.
Teva has made a target of cutting costs by $3B by the end of 2019.
Novartis has found its new chief of oncology.
In his opening presentation at JPM, he highlighted one major product to show how the Irish medtech company is pursuing value-based care.
The financing was co-led by Advantech Capital and SDIC Venture Capital.
PRESS RELEASES